Overview
Autoimmune retinitis encompasses a spectrum of inflammatory conditions affecting the retina, often characterized by vasculitis, retinal aneurysms, and neuroretinitis, with various infectious triggers like Epstein-Barr virus (EBV), varicella zoster virus (VZV), and coronavirus. These conditions can lead to significant visual impairment if not promptly diagnosed and treated.Diagnosis
Clinical Presentation: Acute onset of visual symptoms, perivascular sheathing, retinal vasculitis, and presence of retinal aneurysms 123.
Fundus Examination: Identification of characteristic features such as frosted branch angiitis, macular exudates, and subretinal fluid 1.
Imaging Techniques: Swept-source optical coherence tomography (OCT) and angiography to assess vascular involvement and retinal structure 1.
Serological Testing: Screening for infectious triggers like EBV, VZV, and coronavirus 145.
PCR Testing: For confirmation of viral infections, particularly useful in cases involving VZV post-immunosuppressive therapy 4.Management
Steroids: Intravenous, oral, and topical corticosteroids for managing inflammation 1.
Antiviral Therapy: Valacyclovir for EBV-related conditions 1.
Immunosuppressive Agents: Mycophenolate mofetil (MMF) and adalimumab for refractory cases, often in combination with azathioprine 23.
Laser Photocoagulation: For treating retinal aneurysms and preventing neovascularization 3.
Monitoring: Regular follow-up with multimodal imaging to assess disease progression and treatment efficacy 3.Special Populations
Pediatrics: Frosted branch angiitis can occur in children, requiring prompt steroid intervention 1.
Immunocompromised Patients: Increased vigilance for VZV reactivation leading to sight-threatening complications post-immunosuppressive therapy 4.Key Recommendations
Initiate high-dose intravenous corticosteroids promptly in suspected autoimmune retinitis cases to control inflammation (Evidence: Strong 1).
Consider antiviral therapy (e.g., valacyclovir) in cases linked to EBV infection (Evidence: Moderate 1).
For refractory cases or IRVAN syndrome, incorporate biologic agents like adalimumab alongside conventional immunosuppressants such as azathioprine (Evidence: Weak 2).
Utilize multimodal imaging (OCT, angiography) for monitoring disease activity and treatment response (Evidence: Expert opinion).
In immunocompromised patients, be alert for viral reactivation leading to posterior segment complications and consider PCR testing for rapid diagnosis (Evidence: Moderate 4).References
1 Khanna R, Devishanmani CS, Pradeep S, Biswas J. Multimodal Imaging of a Case of Bilateral Frosted Branch Angiitis in a 5-Year-Old Boy Secondary to Epstein Barr Virus (EBV) Infection. Ocular immunology and inflammation 2024. link
2 B Singh S, Kanakath AV, Saravanan V, K S J, V N. A Case of Idiopathic Retinitis Vasculitis Aneurysms and Neuroretinitis (IRVAN) Treated with Adalimumab. Ocular immunology and inflammation 2023. link
3 Rodríguez Á, Carpio-Rosso W, Rodríguez FJ. Further observations on a bilateral IRVAN syndrome case. International ophthalmology 2019. link
4 Chee YL, Culligan DJ, Olson JA, Molyneaux P, Kurtz JB, Watson HG. Sight-threatening varicella zoster virus infection after fludarabine treatment. British journal of haematology 2000. link
5 Komurasaki Y, Nagineni CN, Wang Y, Hooks JJ. Virus RNA persists within the retina in coronavirus-induced retinopathy. Virology 1996. link
6 Sternberg P, Knox DL, Finkelstein D, Green WR, Murphy RP, Patz A. Acute retinal necrosis syndrome. Retina (Philadelphia, Pa.) 1982. link